CTT Pharma Files a Patent Continuation with the U.S. Patent Office
 |
|||||||||
TheNewswire – August 18, 2026 – CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has filed a patent continuation with the United States Patent Office. This patent application is a continuation of CTT Pharma’s micelle patent in the U.S. and introduces additional claims to pursue broader protection. CTT will continue to spend time enhancing it’s patent portfolio and will keep shareholders posted on all additional patent information as it becomes available.
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company’s patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
Forward-Looking Statements
Forward-looking statements include statements regarding the Company’s plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
CTT Pharmaceutical Holdings, Inc. – 813-606-0060
Copyright (c) 2026 TheNewswire – All rights reserved.
